Patent ID: 11913962
Assignee: UNIVERSITY OF MIAMI
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A method comprising:
(a) identifying or quantifying a risk for reactivation of a latent herpesviridae virus in an immune-compromised mammalian subject from measurement of a T cell subset from a blood sample isolated from the subject,
wherein the measurement of the T cell subset is obtained by
(i) exposing the T cells to one or more antigens from the latent herpesviridae virus, under conditions to stimulate a T cell immune response;
(ii) evaluating individual T cells to detect or measure expression of cytokines IL-2, IFNγ, TNFα, and MIP-1β in the individual T cells;
(iii) evaluating the individual T cells to detect or measure CD8 expression; and

quantifying T cells having a CD8-positive (CD8+), IL-2-positive (IL-2+), IFNγ-positive (IFNγ+), TNFα-positive (TNFα+), MIP-1β-positive (MIP-1β+) phenotype (“PHENOTYPE-P”) from the blood sample; and/or quantifying T cells having a CD8-positive (CD8+), IL-2-negative (IL-2−), IFNγ-positive (IFNγ+), TNFα-negative (TNFα−), MIP-1β-positive (MIP-1β+) phenotype (“PHENOTYPE-N”) from the blood sample,
wherein the quantifying comprises:
quantifying the T cells with the phenotype relative to total T cells analyzed, to generate a relative measure of the quantity of the T cells with the phenotype; and/or
calculating a relative percentage or ratio of PHENOTYPE-P T cells to PHENOTYPE-N T cells;

(b) identifying an elevated or high risk for reactivation of the virus in the subject from the measurement; and
(c) administering, to the subject identified as having the elevated or high risk of viral reactivation, a prophylaxis that comprises an antiviral chemotherapeutic agent, wherein said agent comprises Ganciclovir, Valganciclovir, Foscarnet, Cidofovir, Maribavir, Brincidofovir, or Letermovir.